Standard Biotools Stock Performance
| LAB Stock | USD 1.84 0.02 1.10% |
The entity has a beta of 2.21, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Standard Biotools will likely underperform. At this point, Standard Biotools has a negative expected return of -0.0346%. Please make sure to validate Standard Biotools' coefficient of variation, treynor ratio, skewness, as well as the relationship between the jensen alpha and value at risk , to decide if Standard Biotools performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Standard Biotools has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, Standard Biotools is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Microblink Launches Fraud Lab to Strengthen Identity Fraud Detection with AI | 09/26/2024 |
2 | The age of engagement Taking the Hire Road | 10/03/2024 |
3 | Millennium Management LLC Acquires Shares in Standard BioTools Inc | 10/22/2024 |
4 | Standard BioTools Q3 2024 Earnings Preview | 10/29/2024 |
5 | Standard BioTools Inc Q3 2024 Earnings Call Highlights Navigating Market Challenges with ... | 10/31/2024 |
6 | Standard BioTools Third Quarter 2024 Earnings Beats Expectations | 11/01/2024 |
7 | Standard BioTools appoints Alex Kim as CFO | 11/07/2024 |
8 | Spatial Proteomics Market Projected to Reach USD 264.89 Million by 2032, Driven by a Strong 14.6 percent CAGR Polaris Market Research | 11/18/2024 |
9 | Disposition of 28795 shares by Michael Egholm of Standard Biotools at 1.51 subject to Rule 16b-3 | 11/20/2024 |
10 | Acquisition by Casdin Partners Master Fund, L.p. of 545000 shares of Standard Biotools at 2.05 subject to Rule 16b-3 | 11/25/2024 |
| Begin Period Cash Flow | 82.3 M |
Standard |
Standard Biotools Relative Risk vs. Return Landscape
If you would invest 198.00 in Standard Biotools on September 2, 2024 and sell it today you would lose (14.00) from holding Standard Biotools or give up 7.07% of portfolio value over 90 days. Standard Biotools is generating negative expected returns assuming volatility of 4.0131% on return distribution over 90 days investment horizon. In other words, 35% of stocks are less volatile than Standard, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Standard Biotools Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Standard Biotools' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Standard Biotools, and traders can use it to determine the average amount a Standard Biotools' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0086
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LAB |
Estimated Market Risk
| 4.01 actual daily | 35 65% of assets are more volatile |
Expected Return
| -0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Standard Biotools is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Standard Biotools by adding Standard Biotools to a well-diversified portfolio.
Standard Biotools Fundamentals Growth
Standard Stock prices reflect investors' perceptions of the future prospects and financial health of Standard Biotools, and Standard Biotools fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Standard Stock performance.
| Return On Equity | -0.37 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 408.1 M | ||||
| Shares Outstanding | 372.26 M | ||||
| Price To Earning | (2.52) X | ||||
| Price To Book | 1.40 X | ||||
| Price To Sales | 4.39 X | ||||
| Revenue | 106.34 M | ||||
| Gross Profit | (1.45 M) | ||||
| EBITDA | (54.46 M) | ||||
| Net Income | (74.66 M) | ||||
| Cash And Equivalents | 81.31 M | ||||
| Cash Per Share | 2.68 X | ||||
| Total Debt | 98.21 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 5.87 X | ||||
| Book Value Per Share | 1.23 X | ||||
| Cash Flow From Operations | (43.29 M) | ||||
| Earnings Per Share | (0.69) X | ||||
| Market Capitalization | 684.96 M | ||||
| Total Asset | 323.07 M | ||||
| Retained Earnings | (1 B) | ||||
| Working Capital | 48.89 M | ||||
About Standard Biotools Performance
By analyzing Standard Biotools' fundamental ratios, stakeholders can gain valuable insights into Standard Biotools' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Standard Biotools has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Standard Biotools has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 134.09 | 197.10 | |
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.36) | (0.38) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.46) | (0.48) |
Things to note about Standard Biotools performance evaluation
Checking the ongoing alerts about Standard Biotools for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Standard Biotools help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Standard Biotools generated a negative expected return over the last 90 days | |
| Standard Biotools may become a speculative penny stock | |
| Standard Biotools has high historical volatility and very poor performance | |
| Standard Biotools has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 106.34 M. Reported Net Loss for the year was (74.66 M) with loss before taxes, overhead, and interest of (1.45 M). | |
| Standard Biotools has about 81.31 M in cash with (43.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Standard Biotools has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Acquisition by Casdin Partners Master Fund, L.p. of 545000 shares of Standard Biotools at 2.05 subject to Rule 16b-3 |
- Analyzing Standard Biotools' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Standard Biotools' stock is overvalued or undervalued compared to its peers.
- Examining Standard Biotools' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Standard Biotools' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Standard Biotools' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Standard Biotools' stock. These opinions can provide insight into Standard Biotools' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stocks Directory Find actively traded stocks across global markets | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |